Department of Cell and Cancer Biology

JingYuan Liu, Ph.D.

 

jingyuan liu Jasmine JingYuan Liu, Ph.D.
Associate Professor
Dept. Medicine & Cell and Cancer Biology
jingyuan.liu@utoledo.edu

EDUCATION:

B.Sc. 1995 Biochemistry Shandong Normal University, Jinan, China
M.Sc. 1998 Molecular Genetics Institute of Genetics, Chinese Academy of Sciences, China
Ph.D. 2004 Structure Biology Dept. of Biochemistry & Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA
Post-Doc 2011 Computational Biology Dept. of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA


RESEARCH INTERESTS:

The major research focus of my lab is to understand the interactions between protein-and-protein or between protein-and-compound for drug discovery using bioinformatics and computational approaches and then validate those findings by biophysical and biochemical methods and/or patient data mining such as electronic medical records. Protein-protein interactions are required for biological functions while small compounds that interact with proteins can alter, regulate or trigger protein functions. However, how proteins recognize each other and form a stable complex is not fully understood. Our research incorporates protein dynamics to understand how specific proteins function or interact with other proteins. We develop new algorithms and analytical tools to visualize protein dynamics for a better understanding of protein dynamics and protein function/interactions via mining of simulation data. In addition, we collaborate with other investigators and clinicians to translate our scientific findings to benefit patients. The computational work of my group initially identified proton pump inhibitors (PPIs) as potential inhibitors of Fatty Acid Synthase (FASN). We then conducted data mining of a breast cancer cohort to illustrate the potential effect of PPI usage on the outcome of breast cancer patients. Working with a group of PIs and clinicians, our initial findings have led to phase II clinical trials to repurpose proton pump inhibitors in breast cancer treatment (NCT02595372).


FUNDING:

Ongoing Research Support

R01 GM127656, National Institute of General Medical Sciences
Liu, JingYuan 
2018-2023
Effective targeting survivin dimerization interface with small molecular inhibitors
Role:  PI

R01 CA211904, National Cancer Institute
Zhang, JianTing (PI)
2017-2023
Translational control in Wnt/β-catenin signaling and colon tumorigenesis 
Role:  Co-I

R01 CA219342, National Cancer Institute
Zou, Yue (PI)
ATR isomerization in cellular response to UV damage of DNA
2019-2023
Role:  Co-I

Completed

R41 CA19577, National Cancer Institute
A novel STAT3 inhibitor targeting its DNA binding site for drug development
2016-2018
Role:  PI

PC131242, Department of Defense Prostate Cancer Research Program
Zhang, JianTing (PI)
Targeting survivin to overcome acquired taxol resistance in prostate cancer chemotherapy
Role:  Co-I


BC150290, Department of Defense Breast Cancer Research Program
Zhang, JianTing (PI)
Targeting FASN for breast cancer treatment by repositioning PPIs
Role:  Co-I

PUBLICATIONS:
         PUBMED

 

Last Updated: 6/27/22